How We Ranked These Providers
The compounded GLP-1 market in 2026 is not the market it was in 2024. The bulk-compounding pathway closed in March 2025, hundreds of providers exited or pivoted, and the FDA sent more than 135 warning letters to GLP-1 telehealth operators between September 2025 and February 2026. The providers that came through that period operating in compliance look meaningfully different from the ones that didn't.
Our 2026 rankings weight four factors: clinical model quality (real evaluations, not checkbox forms), pharmacy partner verification (state-licensed 503A operators with clear credentialing), pricing transparency (no surprise upcharges, clear maintenance pricing), and patient experience (intake design, ongoing support, dose flexibility). We excluded providers selling oral tirzepatide products, providers operating without verifiable pharmacy partnerships, and any provider under active FDA enforcement action.
The eight providers below all clear our minimum bar. Where they differ is what they're optimized for — which is why most of them earn category-specific awards rather than competing on a single absolute scale. There's no single "best" compounded GLP-1 provider for everyone, and any list that pretends otherwise is selling you something.
That said, our overall pick for 2026 is Embody, and the rest of the list ranks roughly in the order we'd recommend each provider to a patient with no other constraints. Skip to whichever provider category fits your situation.
The 2026 Rankings
Embody
The polished pick for first-time patients who want the experience to actually feel professional.
Embody emerged in early 2026 as one of the most thoughtfully designed telehealth experiences in the compounded GLP-1 space. The intake includes a real clinical evaluation rather than a checkbox-form charade, dose flexibility is among the broadest in the category, and the program is built around continuity of care rather than one-shot prescription transactions. Pricing is among the most accessible entry points in the market — $149 for the first month (which includes a personalized metabolic report and 1:1 guidance) and $299/month for ongoing refills on the injectable compounded program. Patient support responds in hours, not days, and the underlying pharmacy partnerships are with established 503A operators.
What we like
- $149 first month with metabolic report & 1:1 guidance
- Genuine clinical evaluation in the intake
- Excellent patient support responsiveness
- Custom landing pages with clear program structure
- Dose flexibility for non-standard titration
Trade-offs
- Refill price ($299) is mid-range, not budget-tier
- Newer brand vs. some established competitors
- Best fit for patients who value experience over rock-bottom price
Gala GLP-1
$179/month starting price — the lowest legitimate compounded tirzepatide price we've verified.
Gala launched in early 2026 with one of the most aggressive prices in the legitimate compounded tirzepatide market — $179/month at the entry dose. The program focuses exclusively on injectable compounded semaglutide and tirzepatide (no oral, no questionable combinations), and works with established 503A pharmacy partners. If price is your binding constraint and you've ruled out brand Zepbound on cost, this is the option to look at first.
What we like
- Lowest legitimate starting price in the category
- Injectable-only — no questionable oral products
- Verified 503A pharmacy partners
- Clean, focused program scope
Trade-offs
- Newer entrant — less long-term track record
- Lighter wraparound support than premium competitors
- Pricing scales upward as you reach maintenance doses
SHED
The reliable workhorse that survived every regulatory shift since the original shortage list.
SHED has been operating in the compounded GLP-1 space long enough to weather every regulatory shift since the original tirzepatide shortage listing, and it's one of the more consistently reliable telehealth programs we've tracked. Pricing starts at $297–$299/month for compounded tirzepatide, with a step up to $399/month once you reach the 7.5mg/week dose. SHED is upfront about this transition, which is what matters most. The intake process is efficient without being sloppy, and pharmacy partnerships have stayed compliant through the 2025 transition. SHED is what we'd recommend to a patient who values an established track record over the latest, polished UX.
What we like
- Long operating history through multiple regulatory shifts
- Transparent about the dose-tier pricing transition
- Efficient intake with real clinical evaluation
- Stable pharmacy partner relationships
- HIPAA-compliant, steady clinical support
Trade-offs
- Price jumps from $299 to $399 at maintenance doses
- Less polished UX than newer entrants
- Communication is messaging-only (no live consults)
Care Bare Rx
The smoothest mobile-first intake flow in the compounded GLP-1 space.
Care Bare Rx redesigned its intake flow in early 2026 to be one of the smoothest in the industry — clean, mobile-first, fast without skipping the parts that actually matter clinically. Pricing starts from $199/month and includes the medication plus clinical support, with HSA/FSA payment accepted. The program covers compounded GLP-1 weight management plus adjacent men's health and ED programs through the same login, which makes it a useful one-stop platform if you're managing multiple needs. Coverage is nationwide (all 50 states + Puerto Rico), and the new "Get Started" intake flow is the cleanest example of how to do telehealth onboarding without it feeling like a sketchy quiz funnel.
What we like
- Cleanest mobile intake experience in the category
- $199/mo starting price is among the more competitive
- Multi-program platform (GLP-1, men's health, ED)
- HSA/FSA payment accepted
- Nationwide coverage including Puerto Rico
Trade-offs
- Multi-program scope means GLP-1 isn't a flagship focus
- Less dose-customization depth than specialists
- Limited public-facing reviews (Trustpilot count is low)
MEDVi
For patients who want metabolic care, not just a GLP-1 prescription.
MEDVi differentiates by integrating optional baseline lab work and a more comprehensive clinical workup into the intake. If you want a provider that treats GLP-1 therapy as part of a broader metabolic-health picture rather than a standalone prescription transaction, MEDVi is the one to look at. The "Direct to Quiz" intake flow is fast on the front end, but the underlying clinical model has more depth than the typical competitor — which matters if you have comorbidities, complex meds, or just want a clinician who's actually paying attention.
What we like
- Optional baseline labs integrated into intake
- More comprehensive clinical workup
- Better fit for patients with comorbidities
- Solid 503A pharmacy partnership
Trade-offs
- Higher cost when labs are added
- Slower onboarding if you opt into the comprehensive workup
- Overkill for straightforward weight-loss-only cases
Eden Health
The no-frills option that just works.
Eden Health has carved out a niche as the no-frills option that just works — straightforward intake, transparent flat-rate pricing, and a clinical evaluation that happens quickly without feeling rushed. Compounded semaglutide runs $239/month with no membership fee, and the program includes same-day approval without requiring labs. Tirzepatide pricing is provided post-intake. The 2026 program update tightened the onboarding flow and added more pharmacy partner options for geographic flexibility.
What we like
- Flat-rate pricing with no membership fee
- Same-day approval without required labs
- One-button cancellation process
- LegitScript certified
- Multiple pharmacy partner options
Trade-offs
- Asynchronous check-ins only (every 6 months default)
- Limited publicly available provider info
- Tirzepatide pricing not transparent until after intake
Yucca Health
Competitive pricing with a clinical model we still trust.
Yucca Health is one of the more competitively priced compounded GLP-1 providers we'd still trust on the safety side. The pharmacy partnership (Greenwich Pharmacy) is verifiable, the intake is real, and pricing has stayed consistent through the 2025 regulatory shifts. Current promotional pricing on the 6-month plan: $146/month for compounded semaglutide and $258/month for compounded tirzepatide. Note: Yucca does not provide itemized receipts or Letters of Medical Necessity, so HSA/FSA reimbursement may be harder if your plan administrator requires those documents.
What we like
- Lower-end pricing without obvious quality compromise
- Verified pharmacy partner (Greenwich)
- UPS 2-Day Air shipping included
- 24-hour provider review on average
Trade-offs
- Best pricing requires 6-month commitment
- No itemized receipts or LMNs (HSA/FSA friction)
- Compounded medications can't be returned once shipped
- Lighter wraparound support
TMates
A smaller, newer brand with a sound underlying offer.
TMates is a smaller compounded GLP-1 program worth knowing about as a secondary option. Pricing is competitive, the intake is straightforward, and the underlying offer is sound. We placed it lower on the priority list because the brand is newer and there's less long-term track record to evaluate — but if your top picks aren't a fit for some reason, TMates is a defensible alternative to compare against.
What we like
- Sound underlying program structure
- Competitive mid-range pricing
- Straightforward intake
- Useful as a comparison alternative
Trade-offs
- Less long-term track record to evaluate
- Smaller patient base — fewer aggregate reviews
- Not the strongest in any single category
Synergy Rx
Established operator with a sound underlying program.
Synergy Rx is one of the longer-standing compounded GLP-1 telehealth operators that came through the 2025 regulatory transition with its program structure intact. The intake is straightforward, the pharmacy partnerships are with established 503A operators, and pricing is shared post-intake (a common pattern in this category). We've placed it as honorable mention because the public-facing experience is less polished than our top picks, but the underlying offer is sound — particularly for patients who've ruled out the higher-ranked options or want to compare alternatives.
What we like
- Long operating history through regulatory shifts
- Sound underlying program structure
- Stable 503A pharmacy partnerships
- Useful as a comparison alternative
Trade-offs
- Public-facing experience less polished than top picks
- Pricing not transparent until after intake
- Less differentiation in any specific category
If You'd Rather Skip Compounded Entirely
Worth mentioning: not every patient who searches "best compounded GLP-1 provider" actually wants a compounded product. Some are price-shopping and don't realize the brand-name math has changed. Others are nervous about the regulatory gray zone. Both reactions are reasonable in 2026.
If you'd rather pursue brand-name Zepbound or Mounjaro through a telehealth-style intake — without navigating LillyDirect or your insurance directly — Sesame Care operates a weight-loss program built specifically around prescribing FDA-approved brand-name medications. It's a meaningfully different product from the eight compounded providers above. Sesame doesn't compound, doesn't use the personalization workaround, and prescribes the same medications you'd get at any retail pharmacy.
Sesame Care
Telehealth program that prescribes FDA-approved Zepbound and Mounjaro through standard retail dispensing. The cleanest path if you want telehealth-style convenience but with brand-name product.
Start Sesame intake →For a deeper comparison of compounded vs. brand in 2026, see our companion piece: Compounded Tirzepatide vs Zepbound — Which One Actually Wins for You.
Providers That Didn't Make the List
Without naming specific operators, here's the criteria that disqualified providers from this year's rankings:
- Anyone selling "oral tirzepatide" as a primary product without prescription or real clinical oversight — pills, tablets, capsules, drops, sublingual products. No oral tirzepatide is FDA-approved as of 2026, and the standalone "oral peptides" market is overwhelmingly counterfeit. (A small number of legitimate telehealth providers offer compounded oral formulations as a secondary option for needle-phobic patients within their broader clinical programs — that's a different category from the standalone "oral peptide" sites.)
- Providers operating without verifiable pharmacy partnerships. Every legitimate compounding pharmacy is licensed in at least one state and has a verifiable physical address. If we couldn't confirm both, the provider was excluded.
- Pricing under $100/month for compounded tirzepatide. Real compounded tirzepatide costs money to produce, ship cold, and prescribe. Sub-$100 pricing usually signals counterfeit product or the absence of medical oversight.
- Providers under active FDA enforcement action as of April 2026.
- "Bulk discount" programs with no individual clinical evaluation. Real compounded prescriptions are patient-specific by federal law — bulk-pricing models pretend the law doesn't apply.
- Providers with no physical address, no listed state pharmacy license, and no Certificate of Analysis available on request. Three strikes, you're out.
Several well-known names from the boom-era compounded market are no longer on this list because they've either exited the category, moved exclusively to brand-name prescribing, or shifted to formulations and marketing approaches we can't endorse. The post-2025 market is smaller and stricter, and that's mostly a feature.
FAQ
The Bottom Line
The 2026 compounded GLP-1 market is smaller, stricter, and easier to navigate than what existed two years ago — partly because the regulatory crackdown forced everyone to either tighten up or get pushed to the margins. The eight providers above all clear the legitimacy bar. Where they differ is what they're best at.
If you don't want to think about it: start with Embody. It's our top overall pick for 2026 because it gets the most things right for the most patients.
If price matters most: start with Gala at $179/month.
If you want a brand-name product through telehealth instead of compounded: start with Sesame Care.
The single biggest mistake patients make in this category is treating "cheapest" as the only metric. The second-biggest is assuming all telehealth GLP-1 providers are equivalent. Neither is true. Pick the provider whose strengths match what you're actually optimizing for, and the rest tends to take care of itself.
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. Pricing and regulatory information was current as of April 2026 and may change. Some links in this article are affiliate links — we may earn a commission when you start treatment, at no additional cost to you. Our editorial recommendations are independent of those relationships.